Apellis Pharmaceuticals
Company Type: Therapeutic development
Main focus: Developing novel therapeutics through targeting of complement protein C3
Company stage: Clinical (pre-clinical for gene editing)
Diseases: Liver, retinal, and neurological diseases
Genome-editing tool: Base editing
Funding stage: Post-IPO Debt
Location: Waltham, Massachusetts, USA
Website: https://apellis.com/
Pipeline: https://apellis.com/our-science/our-pipeline/
Partners: Beam Therapeutics
Apellis Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases. The company focuses on inhibiting the complement system via complement protein C3 targeting. Apellis’ broad portfolio includes approved non-gene-editing therapies for the rare disease paroxysmal nocturnal hemoglobinuria and the eye disease geographic atrophy. Apellis recently entered an exclusive collaboration with Beam Therapeutics to develop an undisclosed gene-editing programme.